NCT06911827View on ClinicalTrials.gov

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

QLP2117

Specified dose on specified days

DRUG

QL2107

Specified dose on specified days

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06911827 - A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients | Biotech Hunter | Biotech Hunter